Development of New MDR-Tuberculosis Drugs.

Intro -- DEVELOPMENT OF NEW MDR-TUBERCULOSIS DRUGS -- DEVELOPMENT OF NEW MDR-TUBERCULOSIS DRUGS -- CONTENTS -- PREFACE -- INTRODUCTION -- Chapter 1 RESISTANCE TO COMMONLY USED DRUGS, MECHANISM OF THE ACTION -- ISONIAZID, ETHIONAMIDE -- RIFAMPICIN -- PYRAZINAMIDE -- ETHAMBUTOL -- STREPTOMYCIN -- FLUOROQUINOLONES -- Chapter 2 RESEARCH OF NOVEL MDR-POTENTIAL DRUGS -- 1. STRUCTURE MODIFICATION OF KNOWN COMPOUNDS (INH, ETH, RIF AND RIFAMYCIN DERIVATIVES, PZA, EMB, AND QUINOLONES) -- 2. NEW LEADS WITH NOVEL MECHANISM OF THE ACTION [74] (LINEZOLID, TMC207, PA-824, OPC-67683, BM212, SQ109, FAS20013, LL-3858) -- 3. NOVEL DRUG TARGETS [109] -- 3.1. Cell Wall Biosynthesis -- Cell Wall Structure of M. Tuberculosis [111] -- 3.1.1. Mycolic Acid Synthesis Inhibitors -- Fatty acid biosynthesis [118] -- DesA3 -- 3.1.2. Protein Synthesis Inhibitors [119] -- Inhibition of InhA -- 3.1.3. Polysaccharide Biosynthesis Inhibitors [137] -- Nitrofuranylamides -- 3.2. Targeting P450 Enzymes [148] -- 3.3. Targeting Isocitrate Lyases -- 3.4. FtsZ-Targeting Compounds -- 3.6. Other Targets -- Inhibition of bacterial kinases [164] -- Gyrase Blockers -- Inhibition of Efflux Pumps -- Shikimate Pathway -- Siderophore Biosynthesis -- Biotin Biosynthesis -- Other Potential Targets -- 4. INVESTIGATION OF "NON-ANTI-TUBERCULOUS" DRUGS AND THEIR DERIVATIVES -- 5. OTHER ACTIVE SYNTHETIC COMPOUNDS -- 6. OTHER ACTIVE, NATURALLY-OCCURRING COMPOUNDS -- Chapter 3 CONCLUSION -- ACKNOWLEDGMENTS -- REFERENCES -- INDEX.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.